Canopy Growth Drops Drake: Is it the Trendy Stock it Once Was?

What should investors make of the recent dissolution of the dissolution of Drake’s partnership with Canopy Growth (TSX:WEED)(NYSE:CGC)?

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth (TSX:WEED)(NYSE:CGC) has been making headlines of late. This time, the news centres on the company’s relationship with Canadian rapper Drake.

Canopy Growth has announced it’s severing ties with Drake — a move that seems to have taken the market by surprise.

Here’s what investors should make of this deal.

Canopy Growth pulls the plug on Drake’s More Life

In November 2019, Canopy Growth and Drake announced the launch of More Life, a joint venture that would sell recreational pot and accessories in Canada and around the world. According to the agreement, Canopy decided to turn a Scarborough marijuana cultivation facility into a More Life location for a 40% share in the venture’s equity.

Indeed, it was a hot deal at that time. Companies like Canopy Growth were stumbling over themselves to make celebrity deals. Needless to say, this move garnered significant attention among investors and the media.

This March, Canopy terminated the deal it had in place with Drake. As a result, the company removed the minimum royalty obligations of nearly $33.7 million to More Life from its balance sheet. Canopy’s CEO said that the partnership was not progressing as they had initially intended it would.

Indeed, More Life continues to hold an active trademark for various hemp and cannabis products and accessories. However, I don’t think terminating this deal will be a big blow for this pot player.

Canopy’s mixed track record 

Canopy has had a mixed track record when it comes to celebrity deals. Take, for instance, the Leafs By Snoop brand. This collaboration hasn’t really resulted in much. Leafs by Snoop has managed to put only a handful of products in the domestic market. Comedian Seth Rogen’s Houseplant continues to enjoy some success in the infused beverage space. Lifestyle guru Martha Stewart is also closely associated with Canopy.

That’s a lot of celebrity names for one company to deal with. And these celebrity dealings have generated mixed results. Canopy Growth has a range of specialty branded products and cannabis-infused beverages as a result of these deals. And if more marketing becomes allowed in Canada, Canopy Growth’s portfolio of IP and branded partnerships is top notch.

For now, Canopy Growth is performing just fine, with or without these celebrity deals.

Bottom line

There’s no doubt Canopy Growth has gone mainstream. It’s clear the company isn’t in need of flashy branding deals as it once was. Indeed, Canopy’s cost-cutting efforts appear to be in full swing right now, and I wouldn’t be surprised to see other deals fall apart as a result. Canopy has significantly boosted its operational efficiency metrics, and lowered its SG&A by 41% of late, as a result of such moves.

This is broadly bullish for shareholders, and I think the dissolution of this partnership is largely a non-news event. Investors in Canopy Growth need to stay focused on the long term with this stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »